The DOI matches its Crossref record; 34 of the 36 references it cites were found in a registry or an index.
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Open accessAbstract
BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell carcinoma who had received previous treatment. METHODS: A total of 821 patients with advanced clear-cell renal-cell carcinoma for which they had received previous treatment with one or two regimens of antiangiogenic therapy were randomly assigned (in a 1:1 ratio) to receive 3 mg of nivolumab per kilogram of body weight intravenously every 2 weeks or a 10-mg everolimus tablet orally once daily. The primary end point was overall survival. The secondary end points included the objective response rate and safety. RESULTS: The median overall survival was 25.0 months (95% confidence interval [CI], 21.8 to not estimable) with nivolumab and 19.6 months (95% CI, 17.6 to 23.1) with everolimus. The hazard ratio for death with nivolumab versus everolimus was 0.73 (98.5% CI, 0.57 to 0.93; P=0.002), which met the prespecified criterion for superiority (P≤0.0148). The objective response rate was greater with nivolumab than with everolimus (25% vs. 5%; odds ratio, 5.98 [95% CI, 3.68 to 9.72]; P<0.001). The median progression-free survival was 4.6 months (95% CI, 3.7 to 5.4) with nivolumab and 4.4 months (95% CI, 3.7 to 5.5) with everolimus (hazard ratio, 0.88; 95% CI, 0.75 to 1.03; P=0.11). Grade 3 or 4 treatment-related adverse events occurred in 19% of the patients receiving nivolumab and in 37% of the patients receiving everolimus; the most common event with nivolumab was fatigue (in 2% of the patients), and the most common event with everolimus was anemia (in 8%). CONCLUSIONS: Among patients with previously treated advanced renal-cell carcinoma, overall survival was longer and fewer grade 3 or 4 adverse events occurred with nivolumab than with everolimus. (Funded by Bristol-Myers Squibb; CheckMate 025 ClinicalTrials.gov number, NCT01668784.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Immune checkpoint blockade (ICB), especially targeting the inhibitory receptor programmed cell death 1 (PD-1) expressed on CD8+ T cells, is a highly effective immunotherapy for various cancers.”
From Contrasting cytotoxic and regulatory T cell responses underlying distinct clinical outcomes to anti-PD-1 plus lenvatinib therapy in cancer (2025) · cites this paper as [3]
Experimental — accuracy not yet measuredIn the citing paper
“Primary resistance to ICI is common in patients with both RCC and NSCLC, ranging from 35% to 44% and remains unpredictable [1,3].”
In the citing paper
“Response rates range from 15 to 30% (in most solid tumors) to 45–60% (in melanoma and MSI-H tumors).”
From Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors (2019) · cites this paper as [3]
In the citing paper
“At present, antibodies blocking PD-1 or its ligand PD-L1 have been approved to treat various solid and hematologic malignancies (Table 1) [7–12].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationHapeman, D. E., & Agresti, A. (1991) · Technometrics · doi:10.1080/00401706.1991.10484817 · Cited by 9,407
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Self-citationTHE USE OF CONFIDENCE OR FIDUCIAL LIMITS ILLUSTRATED IN THE CASE OF THE BINOMIAL
Clopper, C. J., & Pearson, E. S. (1934) · Biometrika · doi:10.1093/biomet/26.4.404 · Cited by 5,327
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G. R., Carducci, M. A., Tomczak, P., Dutcher, J. P., Figlin, R. A., Kapoor, A., Starosławska, E., Sosman, J. A., McDermott, D. F., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,645
Self-citation
Flagged first, then by citations
2 of the 36 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Items 101–200 of 1,022
ESMO Symposium on Immuno-Oncology 2015 Officers and Organisation
Bilir, C., Engin, H., Ergen, S., Temi, Y. B., & Morçalı, H. (2015) · Annals of Oncology · doi:10.1093/annonc/ · Cited by 745
The growing role of precision and personalized medicine for cancer treatment
Krzyszczyk, P., Acevedo, A., Davidoff, E. J., Timmins, L. M., Marrero-Berríos, I., Patel, M., White, C., Lowe, C., Sherba, J. J., Hartmanshenn, C., et al. (2018) · TECHNOLOGY · doi:10.1142/s2339547818300020 · Cited by 759
Choueiri, T. K., Halabi, S., Sanford, B. L., Hahn, O. M., Michaelson, M. D., Walsh, M. K., Feldman, D. R., Olencki, T. E., Picus, J., Small, E. J., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.7398 · Cited by 726
Self-citationWNT/β-catenin pathway activation correlates with immune exclusion across human cancers
Luke, J. J., Bao, R., Sweis, R. F., Spranger, S., & Gajewski, T. F. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1942 · Cited by 722
DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells
Sato, H., Niimi, A., Yasuhara, T., Permata, T. B. M., Hagiwara, Y., Isono, M., Nuryadi, E., Sekine, R., Oike, T., Kakoti, S., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01883-9 · Cited by 723
Hendry, S. A., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., de Vijver, K. K. V., Estrada, M. V., Ericsson, P. I. G., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000162 · Cited by 720
Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
Mezzadra, R., Sun, C., Jae, L. T., Gomez-Eerland, R., de Vries, E., Wu, W., Logtenberg, M. E. W., Slagter, M., Rozeman, E. A., Hofland, I., et al. (2017) · Nature · doi:10.1038/nature23669 · Cited by 697
Regulation of PD-L1 expression in the tumor microenvironment
Yi, M., Niu, M., Xu, L., Luo, S., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-01027-5 · Cited by 681
Self-citationKidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E. W., Agarwal, N., Alva, A. S., Baine, M. J., Beckermann, K. E., Carlo, M. I., Choueiri, T. K., Costello, B. A., Derweesh, I., et al. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.0001 · Cited by 687
Self-citationSharma, P., Callahan, M. K., Bono, P., Kim, J. W., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M. A., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 681
Self-citationAnti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 680
Clinicopathological features of acute kidney injury associated with immune checkpoint inhibitors
Cortazar, F. B., Marrone, K. A., Troxell, M. L., Ralto, K. M., Hoenig, M. P., Brahmer, J. R., Le, D. T., Lipson, E. J., Glezerman, I. G., Wolchok, J. D., et al. (2016) · Kidney International · doi:10.1016/j.kint.2016.04.008 · Cited by 666
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in Glioblastoma
Woroniecka, K. I., Chongsathidkiet, P., Rhodin, K. E., Kemeny, H. R., Dechant, C. A., Farber, S. H., Elsamadicy, A. A., Cui, X., Koyama, S., Jackson, C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1846 · Cited by 670
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
Kim, J. M., & Chen, D. S. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw217 · Cited by 648
Fares, C. M., Allen, E. M. V., Drake, C. G., Allison, J. P., & Hu‐Lieskovan, S. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_240837 · Cited by 665
Clear cell renal cell carcinoma ontogeny and mechanisms of lethality
Jonasch, E. W., Walker, C. L., & Rathmell, W. K. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00359-2 · Cited by 667
Cancer immunotherapies targeting the PD-1 signaling pathway
Iwai, Y., Hamanishi, J., Chamoto, K., & Honjo, T. (2017) · Journal of Biomedical Science · doi:10.1186/s12929-017-0329-9 · Cited by 656
The Cancer Genome Atlas of renal cell carcinoma: findings and clinical implications
Linehan, W. M., & Ricketts, C. J. (2019) · Nature Reviews Urology · doi:10.1038/s41585-019-0211-5 · Cited by 644
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade
Lu, S., Stein, J. E., Rimm, D. L., Wang, D. W., Bell, M. A., Johnson, D. B., Sosman, J. A., Schalper, K. A., Anders, R. A., Wang, H., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1549 · Cited by 632
Self-citationTang, T., Huang, X., Zhang, G., Hong, Z., Bai, X., & Liang, T. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00449-4 · Cited by 618
Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles
Ricklefs, F. L., Alayo, Q., Krenzlin, H., Mahmoud, A. B., Speranza, M. C., Nakashima, H., Hayes, J. L., Lee, K., Balaj, L., Passaro, C., et al. (2018) · Science Advances · doi:10.1126/sciadv.aar2766 · Cited by 610
The PD1:PD-L1/2 Pathway from Discovery to Clinical Implementation
Bardhan, K., Anagnostou, T., & Boussiotis, V. A. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00550 · Cited by 606
Development of immuno-oncology drugs — from CTLA4 to PD1 to the next generations
Hoos, A. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2015.35 · Cited by 601
The importance of exosomal PDL1 in tumour immune evasion
Daassi, D., Mahoney, K. M., & Freeman, G. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0264-y · Cited by 598
Saâda-Bouzid, E., Defaucheux, C., Karabajakian, A., Coloma, V. P., Servois, V., Paolettí, X., Even, C., Fayette, J., Guigay, J., Loirat, D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx178 · Cited by 599
Baxi, S. S., Yang, A. W., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L. M., & Korenstein, D. R. (2018) · BMJ · doi:10.1136/bmj.k793 · Cited by 585
Kidney Cancer, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology
Motzer, R. J., Jonasch, E., Agarwal, N., Bhayani, S. B., Bro, W. P., Chang, S. S., Choueiri, T. K., Costello, B. A., Derweesh, I., Fishman, M., et al. (2017) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.0100 · Cited by 575
Self-citationNeurological adverse events associated with immune checkpoint inhibitors: Review of the literature
Cuzzubbo, S., Javeri, F., Tissier, M., Roumi, A., Barlog, C., Doridam, J., Lebbe, C., Belin, C., Ursu, R., & Carpentier, A. F. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.001 · Cited by 571
Improving immune–vascular crosstalk for cancer immunotherapy
Huang, Y., Kim, B. Y. S., Chan, C. K., Hahn, S. M., Weissman, I. L., & Jiang, W. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.145 · Cited by 563
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 576
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape
Emens, L. A., Ascierto, P. A., Darcy, P. K., Demaria, S., Eggermont, A. M. M., Redmond, W. L., Seliger, B., & Marincola, F. M. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.035 · Cited by 576
The foundations of immune checkpoint blockade and the ipilimumab approval decennial
Korman, A. J., Garrett-Thomson, S. C., & Lönberg, N. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00345-8 · Cited by 572
Xu, C., Chen, Y., Du, X.-J., Liu, J.-Q., Huang, C.-L., Chen, L., Zhou, G., Li, W., Mao, Y., Hsu, C., et al. (2018) · BMJ · doi:10.1136/bmj.k4226 · Cited by 566
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 567
Heinhuis, K. M., Ros, W., Kok, M., Steeghs, N., Beijnen, J. H., & Schellens, J. H. M. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy551 · Cited by 563
PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers
Yarchoan, M. M., Albacker, L. A., Hopkins, A. C., Montesion, M., Murugesan, K., Vithayathil, T., Zaidi, N., Azad, N. S., Laheru, D. A., Frampton, G. M., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126908 · Cited by 565
Schalper, K. A., Carleton, M. O., Zhou, M., Chen, T., Feng, Y., Huang, S., Walsh, A. M., Baxi, V. A., Pandya, D., Baradet, T. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0856-x · Cited by 573
Reck, M., Luft, A. V., Szczęsna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L. L. C., Zielinski, C. C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 547
Application of PD-1 Blockade in Cancer Immunotherapy
Wu, X., Gu, Z., Yang, C., Chen, B., Chen, W., Weng, L., & Liu, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.006 · Cited by 541
Makhov, P. B., Joshi, S. S., Ghatalia, P., Kutikov, A., Uzzo, R. G., & Kolenko, V. M. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-1299 · Cited by 539
Optimizing oncolytic virotherapy in cancer treatment
Harrington, K. J., Freeman, D. J., Kelly, E. J., Harper, J. A., & Soria, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0029-0 · Cited by 530
Novel patterns of response under immunotherapy
Borcoman, É., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P. L., & Tourneau, C. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 529
Advances in targeted therapy for esophageal cancer
Yang, Y., Hong, P., Xu, W. W., He, Q., & Li, B. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00323-3 · Cited by 511
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D’Amico, P., Duso, B. A., Vigna, P. D., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 518
Hammers, H. J., Plimack, E. R., Infante, J. R., Rini, B. I., McDermott, D. F., Lewis, L. D., Voss, M. H., Sharma, P., Pal, S. K., Razak, A. R. A., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.72.1985 · Cited by 510
Self-citationRenal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Escudier, B. J., Porta, C., Schmidinger, M., Rioux-Leclercq, N. C., Bex, A., Khoo, V. S., Gruenvald, V., & Horwich, A. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw328 · Cited by 504
Self-citationNishino, M., Ramaiya, N. H., Awad, M. M., Sholl, L. M., Maattala, J. A., Taibi, M., Hatabu, H., Ott, P. A., Armand, P. A., & Hodi, F. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1320 · Cited by 502
Lan, Y., Zhang, D., Xu, C., Hance, K. W., Marelli, B., Qi, J., Yu, H., Qin, G., Sircar, A., Hernández, V. M., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5488 · Cited by 502
de Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., Schutz, F. A. B., Joaquim Bellmunt, B., Sonpavde, G., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0237 · Cited by 498
Self-citationImmune checkpoint inhibitor–related dermatologic adverse events
Geisler, A. N., Phillips, G. S., M.S, D. M. B., Wu, J., Leung, D. Y. M., Moy, A. P., Kern, J. A., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.132 · Cited by 502
Omuro, A., Vlahovic, G., Lim, M., Sahebjam, S., Baehring, J., Cloughesy, T., Voloschin, A., Ramkissoon, S. H., Ligon, K. L., Latek, R., et al. (2018) · Neuro-Oncology · doi:10.1093/neuonc/nox208 · Cited by 486
Cancer immunotherapies: advances and bottlenecks
Rui, R., Zhou, L., & He, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1212476 · Cited by 484
mTOR: Role in cancer, metastasis and drug resistance
Murugan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.003 · Cited by 483
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Self-citationWang, P., Chen, Y., Song, S., Wang, T., Ji, W., Li, S., Liu, N., & Yan, C. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00730 · Cited by 479
The inflammatory microenvironment and microbiome in prostate cancer development
Sfanos, K. S., Yegnasubramanian, S., Nelson, W. G., & Marzo, A. M. D. (2017) · Nature Reviews Urology · doi:10.1038/nrurol.2017.167 · Cited by 477
Synthetic lethality as an engine for cancer drug target discovery
Huang, A., Garraway, L. A., Ashworth, A., & Weber, B. L. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0046-z · Cited by 490
Immunotherapy and Prevention of Pancreatic Cancer
Morrison, A. H., Byrne, K. T., & Vonderheide, R. H. (2018) · Trends in cancer · doi:10.1016/j.trecan.2018.04.001 · Cited by 475
Targeting T Cell Co-receptors for Cancer Therapy
Callahan, M. K., Postow, M. A., & Wolchok, J. D. (2016) · Immunity · doi:10.1016/j.immuni.2016.04.023 · Cited by 480
The biology of Hepatocellular carcinoma: implications for genomic and immune therapies
Khemlina, G., Ikeda, S., & Kurzrock, R. (2017) · Molecular Cancer · doi:10.1186/s12943-017-0712-x · Cited by 473
Sanmamed, M. F., Perez‐Gracia, J. L., Schalper, K. A., Fusco, J. P., González, Á., Rodriguez-Ruiz, M. E., Oñate, C., Perez, G., Alfaro, C., Martín‐Algarra, S., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx190 · Cited by 470
Primary and Acquired Resistance to Immune Checkpoint Inhibitors in Metastatic Melanoma
Gide, T. N., Wilmott, J. S., Scolyer, R. A., & Long, G. V. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2267 · Cited by 469
PD-1–PD-L1 immune-checkpoint blockade in B-cell lymphomas
Goodman, A. M., Patel, S. P., & Kurzrock, R. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.168 · Cited by 459
Prat, A., Navarro, A., Paré, L., Reguart, N., Galván, P., Pascual, T., Martínez, A., Nuciforo, P., Comerma, L., Alos, L., et al. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3556 · Cited by 455
PD‐1/PD‐L1 pathway: Basic biology and role in cancer immunotherapy
Salmaninejad, A., Valilou, S. F., Shabgah, A. G., Aslani, S., Alimardani, M., Pasdar, A., & Sahebkar, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.28358 · Cited by 445
Teaching an old dog new tricks: next-generation CAR T cells
Tokarew, N. J. A., Ogonek, J., Endres, S., von Bergwelt‐Baildon, M., & Kobold, S. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0325-1 · Cited by 457
'Final common pathway' of human cancer immunotherapy: targeting random somatic mutations
Tran, E., Robbins, P. F., & Rosenberg, S. A. (2017) · Nature Immunology · doi:10.1038/ni.3682 · Cited by 443
IDO1 in cancer: a Gemini of immune checkpoints
Zhai, L., Ladomersky, E., Lenzen, A. C., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 448
The immunology of renal cell carcinoma
Diaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 447
Tumor Microenvironment Dynamics in Clear-Cell Renal Cell Carcinoma
Vuong, L. H., Kotecha, R. R., Voss, M. H., & Hakimi, A. A. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0499 · Cited by 443
Harrington, K. J., Ferris, R. L., Blumenschein, G. R., Colevas, A. D., Fayette, J., Licitra, L. F., Kasper, S., Even, C., Vokes, E. E., Worden, F. P., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30421-7 · Cited by 429
Krishna, C., DiNatale, R. G., Kuo, F., Srivastava, R. M., Vuong, L. H., Chowell, D., Gupta, S., Vanderbilt, C., Purohit, T. A., Liu, M., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.03.007 · Cited by 448
Self-citationResistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
Lei, Q., Wang, D., Sun, K., Wang, L., & Zhang, Y. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00672 · Cited by 431
Danaher, P. J., Warren, S. E., Lu, R. O., Samayoa, J. A., Sullivan, A. H., Pekker, I., Wallden, B., Marincola, F. M., & Cesano, A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0367-1 · Cited by 419
Wang, H., Rong, X., Zhao, G., Zhou, Y., Xiao, Y., Ma, D., Jin, X., Wu, Y., Yan, Y., Yang, H., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.02.010 · Cited by 411
Morris, V. K., Salem, M. E., Nimeiri, H. S., Iqbal, S., Singh, P. P., Ciombor, K. K., Polite, B. N., Deming, D. A., Chan, E. W., Wade, J. L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30104-3 · Cited by 409
Self-citationInnate immune signaling and regulation in cancer immunotherapy
Corrales, L., Matson, V., Flood, B., Spranger, S., & Gajewski, T. F. (2017) · Cell Research · doi:10.1038/cr.2016.149 · Cited by 408
Sharma, P., Pachynski, R. K., Narayan, V., Fléchon, A., Gravis, G., Galsky, M. D., Mahammedi, H., Patnaik, A., Subudhi, S. K., Ciprotti, M., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.007 · Cited by 406
Self-citationStrauss, J., Heery, C. R., Schlom, J., Madan, R. A., Cao, L., Kang, Z., Lamping, E., Marté, J. L., Donahue, R. N., Grenga, I., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2653 · Cited by 406
Eigentler, T., Hassel, J. C., Berking, C., Aberle, J., Bachmann, O. P., Grünwald, V., Kähler, K. C., Loquai, C., Reinmuth, N., Steins, M. B., et al. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.02.003 · Cited by 410
Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2016) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 404
Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy
Meng, X., Huang, Z., Teng, F., Xing, L., & Yu, J. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.11.001 · Cited by 407
Organoid Models of Tumor Immunology
Yuki, K., Cheng, N., Nakano, M., & Kuo, C. J. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.06.010 · Cited by 418
Paradigms on Immunotherapy Combinations with Chemotherapy
Salas‐Benito, D., Perez‐Gracia, J. L., Ponz‐Sarvisé, M., Rodriguez-Ruiz, M. E., Martínez‐Forero, I., Álvarez, E. C., López-Picazo, J. M., Sanmamed, M. F., & Melero, I. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1312 · Cited by 409
Spranger, S., Luke, J. J., Bao, R., Zha, Y., Hernandez, K. M., Yan, L., Gajewski, A. P., Andrade, J., & Gajewski, T. F. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1609376113 · Cited by 403
Derosa, L., Routy, B., Fidelle, M., Iebba, V., Alla, L., Pasolli, E., Segata, N., Desnoyer, A., Pietrantonio, F., Ferrere, G., et al. (2020) · European Urology · doi:10.1016/j.eururo.2020.04.044 · Cited by 398
Self-citationHuinen, Z. R., Huijbers, E. J. M., B, J. R. V. B., Nowak-Sliwinska, P. M., & Griffioen, A. W. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00496-y · Cited by 415
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Cappelli, L. C., Gutierrez, A. K., Baer, A. N., Albayda, J., Manno, R., Haque, U. J., Lipson, E. J., Bleich, K. B., Shah, A. A., Naidoo, J., et al. (2016) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209595 · Cited by 402
Courtney, K. D., Infante, J. R., Lam, E. T., Figlin, R. A., Rini, B. I., Brugarolas, J., Zojwalla, N. J., Lowe, A. M., Wang, K., Wallace, E. M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.2627 · Cited by 393
Self-citationAtkins, M. B., & Tannir, N. M. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.07.009 · Cited by 400
European Association of Urology Guidelines on Renal Cell Carcinoma: The 2025 Update
Bex, A., Abu‐Ghanem, Y., Albiges, L. K., Bonn, S. E., Campi, R., Umberto Capitanio, A., Dabestani, S., Hora, M., Klatte, T., Kuusk, T., et al. (2025) · European Urology · doi:10.1016/j.eururo.2025.02.020 · Cited by 392
Siska, P. J., Beckermann, K. E., Mason, F. M., Andrejeva, G., Greenplate, A. R., Sendor, A. B., Chiang, Y.-C. J., Corona, A. L., Gemta, L. F., Vincent, B. G., et al. (2017) · JCI Insight · doi:10.1172/jci.insight.93411 · Cited by 389
Mitchell, T. C., Hamid, O., Smith, D. C., Bauer, T. M., Wasser, J. S., Olszanski, A. J., Luke, J. J., Balmanoukian, A. S., Schmidt, E. V., Zhao, Y., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.78.9602 · Cited by 388
Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer
Suresh, K. S., Naidoo, J., Lin, C. T., & Danoff, S. K. (2018) · CHEST Journal · doi:10.1016/j.chest.2018.08.1048 · Cited by 392
Simonaggio, A., Michot, J., Voisin, A.-L., Pavec, J. L., Collins, M., Lallart, A., Cengizalp, G., Vozy, A., Laparra, A., Varga, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.1022 · Cited by 395
Kudo, T., Hamamoto, Y., Kato, K., Ura, T., Kojima, T., Tsushima, T., Hironaka, S., Hara, H., Satoh, T., Iwasa, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30181-x · Cited by 384
Samson, A., Scott, K. J., Taggart, D., West, E. J., Wilson, E., Nuovo, G. J., Thomson, S., Corns, R. A., Mathew, R. K., Fuller, M. J., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aam7577 · Cited by 383
Orillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Atkins, M. B., Plimack, E. R., Puzanov, I. J., Fishman, M., McDermott, D. F., Cho, D. C., Vaishampayan, U. N., George, S., Olencki, T. E., Tarazi, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30081-0 · Cited by 372
Self-citationEpigenetic silencing by SETDB1 suppresses tumour intrinsic immunogenicity
Griffin, G. K., Wu, J., Iracheta-Vellve, A., Patti, J. C., Hsu, J., Davis, T., Dele-Oni, D., Du, P. P., Halawi, A. G., Ishizuka, J. J., et al. (2021) · Nature · doi:10.1038/s41586-021-03520-4 · Cited by 370
Metadata
- Authors
- Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., Castellano, D., Choueiri, T. K., Gurney, H., Donskov, F., Bono, P., Wagstaff, J., Gauler, T. C., Ueda, T., Tomita, Y., Schutz, F. A., Kollmannsberger, C., Larkin, J., Ravaud, A., Simon, J. S., Xu, L.-A., Waxman, I. M., & Sharma, P.
- Affiliations
- Brigham and Women's Hospital (US)
- Institut Gustave Roussy (FR)
- Beth Israel Deaconess Medical Center (US)
- Roswell Park Comprehensive Cancer Center (US)
- Sidney Kimmel Comprehensive Cancer Center (US)
- Stanford Cancer Institute (US)
- University of Washington (US)
- Vanderbilt University Medical Center (US)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Fox Chase Cancer Center (US)
- Hospital Universitario 12 De Octubre (ES)
- Westmead Hospital (AU)
- Aarhus University Hospital (DK)
- University of Helsinki (FI)
- Swansea University (GB)
- Essen University Hospital (DE)
- Chiba Cancer Center (JP)
- Niigata University (JP)
- Beneficência Portuguesa de São Paulo (BR)
- BC Cancer Agency (CA)
- Royal Marsden Hospital (GB)
- Centre Hospitalier Universitaire de Bordeaux (FR)
- Bristol-Myers Squibb (United States) (US)
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Motzer, Robert J.
- Escudier, Bernard
- McDermott, David F.
- George, Saby
- Hammers, Hans J.
- Tykodi, Scott S.
- Sosman, Jeffrey A.
- Procopio, Giuseppe
- Plimack, Elizabeth R.
- Castellano, Daniel
- Choueiri, Toni K.
- Gurney, Howard
- Donskov, Frede
- Bono, Petri
- Wagstaff, John
- Gauler, Thomas C.
- Ueda, Takeshi
- Tomita, Yoshihiko
- Schutz, Fabio A.
- Kollmannsberger, Christian
- Larkin, James
- Ravaud, Alain
- Sharma, Padmanee
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-11-05
- Volume
- 373
- Issue
- 19
- Pages
- 1803-1813
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC5719487
- OpenAlex
- W2222086386
- Cited by
- 5,807
- References
- 36
- Citations by year
- 2026: 173 · 2025: 255 · 2024: 367 · 2023: 449 · 2022: 535 · 2021: 669 · 2020: 723 · 2019: 669 · 2018: 719 · 2017: 691 · 2016: 511 · 2015: 36
- FWCI
- 515.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Ghent University Academic Bibliography (Ghent University) (submittedVersion, other-oa)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Lirias (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Funders
- National Cancer Institute (P30CA008748)
- Topics
- Health Sciences › Medicine › Oncology › Renal cell carcinoma treatment
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- nivolumab, everolimus, PD-1 inhibitors, mTOR inhibitors, overall survival, objective response rate, progression-free survival, treatment-related adverse events, anti-angiogenic therapy, immune checkpoint inhibitors, mTOR inhibition, fatigue, anemia, previously treated patients
- MeSH terms
- Everolimus, Nivolumab, Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Middle Aged, Quality of Life, Survival Analysis, Sirolimus, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
